Low miR-214-5p Expression Correlates With Aggressive Subtypes of Pediatric ALCL With Non-Common Histology

Frontiers in Oncology

Stefania Bortoluzzi¹  Luca Lo Nigro²  Enrico Gaffo³  Rossella Mura⁴  Marta Pillon⁵  Elisa Carraro⁵  Federica Lovisa⁶  Piero Di Battista⁶  Carlotta C. Damanti⁶  Alessandra Biffi⁶  Lara Mussolin⁶  Lavinia Ferrone⁶  Ilaria Gallingani⁶  Anna Garbin⁶  Vincenza Guzzardo⁷  Marco Pizzi⁷  Angelo Paolo Dei Tos⁷ 

[1] CRIBI Interdepartmental Research Center for Innovative Biotechnologies (CRIBI), University of Padova, Padova, Italy;Center of Pediatric Hematology Oncology, Azienda Policlinico G. Rodolico – San Marco, Catania, Italy;Department of Molecular Medicine, University of Padova, Padova, Italy;Department of Paediatric Haematology-Oncology, Ospedale Pediatrico Microcitemico, Cagliari, Italy;Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Maternal and Child Health Department, University of Padova, Padova, Italy;Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy;Surgical Pathology and Cytopathology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy;

关键词: ALCL;    childhood;    miRNA;    prognosis;    biomarker;    RNA-seq;   

DOI  :  10.3389/fonc.2021.663221

来源: DOAJ

【 摘 要 】

The unsatisfactory cure rate of relapsing ALK-positive Anaplastic Large-Cell Lymphoma (ALCL) of childhood calls for the identification of new prognostic markers. Here, the small RNA landscape of pediatric ALK-positive ALCL was defined by RNA sequencing. Overall, 121 miRNAs were significantly dysregulated in ALCL compared to non-neoplastic lymph nodes. The most up-regulated miRNA was miR-21-5p, whereas miR-19a-3p and miR-214-5p were reduced in ALCL. Characterization of miRNA expression in cases that relapsed after first line therapy disclosed a significant association between miR-214-5p down-regulation and aggressive non-common histology. Our results suggest that miR-214-5p level may help to refine the prognostic stratification of pediatric ALK-positive ALCL.

【 授权许可】

Unknown